Answers are grounded in this paper and cite their sources.
Demonstrates dynamic tumor response in metastatic solid tumors, indicating potential therapeutic targets.
Studies on the dynamic changes occurring in the tumor microenvironment (TME) following CAR-T cell therapy have been confounded by host lymphodepletion, multiple dosing and immunodeficient models. Here, a nanobody-based, mouse mesothelin-targeting CAR-T cell (A101) was developed, achieving effective primary tumor suppression, metastasis reduction, and improved survival after a single dose in immunocompetent, syngeneic mouse models without lymphodepletion. Temporal tumor profiling using RNA sequencing revealed initial downregulation of cell proliferation genes followed by upregulation of inflammation, epithelial-to-mesenchymal-transition (EMT) and extracellular matrix (ECM) modification genes in the CAR-T-treated tumors relative to mock-T-treated controls. This phenotype was reversed at a later timepoint which coincided with downregulation of immunosuppressive Cd274 + Lcn2 + neutrophils and upregulation of anti-tumor P2rx1 + Nrf2 - neutrophils. At the same time, upregulation of Ccl2 + in fibroblasts and a more immunomodulatory macrophage phenotype was observed in CAR-T-treated tumors, indicating a tumor adaptation mechanism. This study demonstrates complex dynamic changes in the TME, and highlights time-dependent responses of solid tumors to CAR-T cell therapy. It further highlights Lcn2 + neutrophils and Ccl2 + fibroblasts as potential therapeutic targets for improving CAR-T cell anti-tumor efficacy. Abstract Figure Graphical abstract. Tumor responses to A101 CAR-T cell treatment.
No takes yet. Share an insight, caveat, or question.
Stathopoulou et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: